Decisions about targeted therapy, such as choosing certain tyrosine kinase inhibitors for individuals with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations in lung cancer mutations, might be aided by ctDNA analysis [34]. This evidence concerns the gene ALK and lung cancer.